pharmaceutical stocks Archives

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. 3 days ago 161Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Investor-themed graphic showing Tribe Public and ACOG logos above a rising green-and-gold stock chart, dollar signs, and the Zunveyl (benzgalantamine) 5 mg, 10 mg, and 15 mg branding against a modern city backdrop.

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

by John F. Heerdink, Jr. September 6, 2026 158Views 0Likes

Alpha Cognition Inc. (NASDAQ: ACOG) has moved meaningfully beyond the familiar small-cap biotech ritual of promising future potential. Since CEO Michael McFadden’s January 15, 2026 Tribe Public luncheon presentation during the J.P. Morgan Healthcare Conference week in San Francisco, the company has paired…

Comic-book-style illustration of a confident superhero in a teal suit with an “R” molecular symbol flying above a modern city skyline. Large headline text reads “Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention,” while surrounding signs reference Revolution Medicines, RVMD stock, innovation, cancer breakthrough and oncology leadership.

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

by John F. Heerdink, Jr. September 1, 2026 200Views 0Likes

Revolution Medicines, Inc. (NASDAQ: RVMD) seems to have crossed the line that separates a compelling biotech hypothesis from a commercial oncology story: the U.S. Food and Drug Administration approved its first medicine, RASONQUE (daraxonrasib), for certain adults with metastatic pancreatic adenocarcinoma. The approval…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 201Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Promotional graphic for Tribe Public’s Eupraxia Pharmaceuticals webinar, “Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story,” featuring CEO James Helliwell, MD; EoE inflammation imagery, precision-healing graphics and event details for Friday, August 21, 2026.

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. August 21, 2026 328Views 0Likes

Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…

Tag: pharmaceutical stocks

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

Revolution Medicines’ Moment Arrives: Why RVMD Has Wall Street’s Attention -( $IBB $RVMD $XBI )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI )

Your Guide To Staying Informed In The Markets